1. Introduction {#sec1}
===============

Breast cancer is the most common type of cancer in women all over the world. Based on the latest estimation, 268,600 women will be diagnosed with breast cancer and 41,760 breast cancer death will occur in 2019 among women in the United States[@bib1]. Although the death rate has been partially declined during the past two decades, breast cancer still accounts for the second leading cause of cancer death among women. According to the classification by molecular subtypes, breast cancer can be classified by the expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)[@bib2]. Breast cancer with none of these receptors are classified as triple negative breast cancer (TNBC), which lacks efficient treatment strategies[@bib3]. Recently, the tumor suppressor breast cancer susceptible gene 1 (*BRCA1*) was found to be frequently mutated among the TNBC patients[@bib4]. BRCA1 is responsible for the repair of DNA double-strand breaks and thus is important for maintaining genomic integrity[@bib5]. In addition, BRCA1 also takes part in transcription regulation and cell cycle control[@bib6]. With its high mutational frequency in the triple negative breast cancer and its functional participation in a wide-spectrum of cellular pathways, BRCA1 is recognized as an emerging target for the treatment of TNBC[@bib7].

BRCA1 forms several distinct complexes with associated proteins and participates in the repair of DNA double-strand breaks by homologous recombination. Depending on the complex proteins, BRCA1 complexes have been divided into at least four complexes, including BRCA1-A, -B, -C and -D. Each complex has unique associated proteins that function to recruit BRCA1 to DNA damage foci and catalyze DNA damage repair[@bib8]. The dysfunction in BRCA1 could lead to the failure of DNA damage repair, causing the cells sensitive to DNA damaging agents. Based on this feature, poly (ADP-ribose) polymerase 1 (PARP1) inhibitors have been developed as synthetic lethality drugs for BRCA1 deficient breast cancer cells[@bib7]. PARP1 is an enzyme participating in the repair of DNA single-strand breaks. The single-strand breaks (nicks), if not repaired, will form double-strand breaks when DNA replication occurs at the site of the nicks, which then require BRCA1-mediated DNA repair system. By this mechanism, the combination of PARP inhibition and BRCA1 deficiency induces a synthetic lethality in the cells where multiple DNA double strand-breaks are formed[@bib9]. This finding prompted the development of several PARP inhibitors for the treatment of BRCA1-deficient breast and ovarian cancers, such as olaparib, rucaparib and niraparib, which have successfully reached to clinic recently[@bib10].

To further exploit the synthetic lethality approach to target BRCA1 mutant breast cancer, we previously screened an epigenetics compound library in BRCA1-isogenic breast cancer pairs. From the study we found several synthetic lethality targets, including bromodomain and extra-terminal domain (BET)[@bib11]. We have elaborated the mechanism of the synthetic lethality between BET and BRCA1, *i*.*e*., BET inhibition abrogated MYC-dependent transcription repression of a redox regulator, thioredoxin-interacting protein (TXNIP) by switching MYC to MondoA:MLX complex on *TXNIP* promoter. This led to the elevated cellular reactive oxygen species (ROS) and DNA damages that are detrimental to BRCA1-deficient breast cancer cells[@bib11]. In addition to BET, we also identified histone deacetylase (HDAC) as potential synthetic lethality targets for BRCA1. HDACs are a class of enzymes that remove acetyl groups from lysine residues on histones. By modifying neutral histone tails to positively charged ones, HDACs allow the DNA to tightly bind to histones and functions as a transcription corepressor[@bib12]. HDAC family of proteins are involved in a variety of biological processes and recognized as a target of anticancer drugs.

In this study, we report that the inhibition of class I HDAC increases the transcription of *TXNIP*, an inhibitor of major antioxidant protein thioredoxin[@bib13]. High expression of TXNIP induces cellular oxidative stress by elevating ROS and preferentially increases DNA damage and apoptosis in BRCA1-deficient breast cancer cells. We further show that the combination of inhibitors of BET and HDAC significantly enhances synthetic lethality effect in BRCA1-deficient breast cancer cells. Our study provides a novel, druggable synthetic lethality target for BRCA1 that can be used as a single or in combination with other synthetic lethality drugs.

2. Material and methods {#sec2}
=======================

2.1. Cell culture {#sec2.1}
-----------------

The establishment and culture condition for T47D and HCC1937 BRCA1 isogenic cell lines were described previously[@bib14]. BRCA1 wild type (MDA-MB-468, MCF-7) and mutant (MDA-MB-436, SUM-149) breast cancer cell lines were cultured in DMEM (Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco) and maintained in a CO~2~ incubator adjusted at 5%.

2.2. Reagents and antibodies {#sec2.2}
----------------------------

Entinostat (DC6909) was bought from DC chemicals (Shanghai, China). Vorinostat (S1047) and Mocetinostat (S1122) were from Selleck chemicals (Houston, TX, USA). The siRNAs and primers were purchased from Integrated DNA Technologies (Coralville, IA, USA) and the sequence information is shown in [Supporting Information Tables S1 and S2](#appsec1){ref-type="sec"}. Primary antibodies against BRCA1 (sc-642), heme oxygenase 1 (HO-1) (sc-136960), GAPDH (sc-365062), PARP1 (sc-7150), acetyl-histone H4 (sc-8662) and histone H4 (sc-25260) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Primary antibodies against phospho-histone H2A.X (*γ*-H2AX) (Ser139) (\#9718S), TXNIP (\#14715S) and cleaved caspase-3 (\#9661S) were purchased from Cell Signaling Technology (Danvers, MA, USA). Primary antibody against MLXIP was from Proteintech (Rosemont, IL, USA). Secondary antibodies conjugated with horseradish peroxidase (HRP) were all purchased from Santa Cruz Biotechnology. The dilution factors of different antibodies can be found in [Supporting Information Table S3](#appsec1){ref-type="sec"}.

2.3. siRNA transfection {#sec2.3}
-----------------------

TXNIP siRNA was synthesized by Integrated DNA Technologies, Inc. In brief, 2 nmol/L of TXNIP siRNA was dissolved and incubated in Opti-MEM (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with Lipofectamine RNAi max reagent (Thermo Fisher Scientific) for 20 min. After that, the siRNA solution was added to the cells directly. Twenty-four hours later, drugs were added to the cells for evaluation. The sequence information of TXNIP siRNA can be found in [Table S1](#appsec1){ref-type="sec"}.

2.4. Cell viability and clonogenic assays {#sec2.4}
-----------------------------------------

For cell viability assay, cells were seeded in a 96-well plate at a density of 5 × 10^3^ cells/well. After cells were allowed to adhere for 24 h, drugs were added and the incubation was continued for 72 h. The cell viability was evaluated by measuring the Alamarblue fluorescence at Ex560/Em590 with a SpectraMax M5 fluorescence microplate reader (Molecular Devices, Sunnyvale, CA, USA). GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA) was used for the curve fitting of cell growth inhibition and analysis. For clonogenic assay, cells (2 × 10^3^ cells/well) were plated in a 6-well plate and drugs were added 24 h post cell plating. Cells were incubated with or without drugs for 15 days until visible colonies were formed. The crystal violet regent was added to the cells for staining cell colonies.

2.5. Measurement of apoptosis {#sec2.5}
-----------------------------

Cellular apoptosis was evaluated with three different assays, including sub-G1 cell population, annexin V staining and Hoechst33342 (HO33342) staining. For sub-G1 cell population, cells were first fixed with 75% of ice-cold ethanol for 24 h. Cells were then gently washed with PBS for three times and stained with 50 μg/mL propidium iodide (PI), 100 μg/mL RNase A and 0.2% Triton X-100 for 30 min. Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA) was used for the cell cycle and sub-G1 population analysis. For annexin V staining, we used a staining kit from BioLegend (San Diego, CA, USA) and followed the manufacturer\'s instructions. Briefly, cells were co-stained with annexin V and propidium iodide regents for 30 min. Then the cells were washed by PBS and collected for test on flow cytometry. The data was analyzed with FlowJo software (FlowJo LLC, Ashland, OR, USA). For HO33342 nuclear staining, cells treated with drugs for 72 h were incubated with HO33342 at a final concentration of 0.1 μg/mL. The live-cell nuclear images were captured with Zeiss AxioObserver Z1 fluorescence microscope (Carl Zeiss, Thornwood, NY, USA).

2.6. RNA sequencing {#sec2.6}
-------------------

Total RNA from cells treated with or without drugs for 24 h was isolated with RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). The RNA integrity number (RIN) values were assessed with RNA 6000 Nano Kit on 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) and were used for RNA quality evaluation. mRNA was extracted from the total RNA using NEBNext Poly(A) mRNA Magnetic Isolation Module (E7490S, New England Biolabs, Ipswich, MA, USA). cDNA library was prepared from mRNA by NEBNext Ultra Directional RNA Library Prep Kit for Illumina (E7420S, New England Biolabs). The library quality was evaluated using High Sensitivity DNA Analysis Kit on 2100 Bioanalyzer. RNA sequencing was performed with Illunima Hiseq 2500 (Illumina, San Diego, CA, USA). The raw data was analyzed with TopHat and Cuffdiff software[@bib15], [@bib16]. The gene expression profiles were uploaded to Reactome pathway database (<https://reactome.org/>) for signal pathway analysis.

2.7. Quantitative reverse transcription PCR {#sec2.7}
-------------------------------------------

Total RNA was isolated from cells with RNeasy Mini Kit (Qiagen). cDNA was prepared with High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). The iTaq Universal SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) was used for amplification of transcripts in an ABI-7500 Real-Time PCR System (Thermo Fisher Scientific). *GAPDH* transcript was used as an internal reference. Comparative CT values were determined to evaluate relative mRNA expression changes.

2.8. Western blotting {#sec2.8}
---------------------

Total protein was extracted from cells with a radioimmunoprecipitation assay (RIPA) buffer. The quantification of protein was conducted with BCA Protein Assay Kit (Thermo Fisher Scientific). Equal amount of protein was loaded and separated *via* SDS-PAGE gels, and transferred to PVDF membranes. Membranes were blocked with 5% non-fat dried milk (Santa Cruz Biotechnology) and incubated with primary antibodies diluted in a blocking solution at 4 °C overnight. After washing, membranes were incubated with secondary antibodies for additional 2 h at room temperature. Blots were then incubated with Clarity™ Western ECL Substrate (Bio-Rad) and specific protein bands were analyzed under a ChemiDoc MP imaging system (Bio-Rad).

2.9. Chromatin immunoprecipitation (ChIP) {#sec2.9}
-----------------------------------------

ChIP assay was performed with Imprint Chromatin Immunoprecipitation Kit (Sigma--Aldrich, St. Louis, MO, USA) according to the manufacturer\'s instructions. In brief, HCC1937 *BRCA1*^−/−^ cells were treated with DMSO or 5 μmol/L of entinostat for 6 h. Then, 1% formaldehyde was added to the cells to crosslink DNA and proteins. The cell nuclear fraction was prepared with Nuclei Preparation Buffer. After that, shearing buffer was added to the samples for sonication by Bioruptor Sonication System (Diagenode, Denville, NJ, USA). The samples were incubated with rabbit anti-IgG or anti-acetyl-histone H4 antibody which were trapped on protein A-coated assay strips. The precipitated DNA was used for RT-qPCR with the primer pair that targets to the promoter region of *TXNIP*. The primer sequences are listed in [Table S2](#appsec1){ref-type="sec"}.

2.10. Animal experiments {#sec2.10}
------------------------

All animal experiments were carried out in accordance with the approved animal protocol by Animal Research Ethics Committee of the University of Macau, China. For the HCC1937 BRCA1 isogenic model, 4--6 weeks old NOD-SCID mice (5 mice/group) were used for generation of the xenograft models. Approximately 5 × 10^6^ of BRCA1 wildtype or deficient cells were inoculated bilaterally (right and left flanks) in each mouse. Mice were randomized when the mean volume of tumors reached 100 mm^3^. Vehicle (5% DMSO, 5% tween-80 and 5% polyethylene glycol-400 in sterile saline) or entinostat (10 and 20 mg/kg) was administered to the mice *via* intraperitoneal injection for 14 days (once daily). After stopping drug administration, mice and tumor growth were continuously monitored for additional 25 days. For T47D BRCA1 isogenic model, 4--6 weeks old BALB/c nude mice (4 mice/group) were used for establishing a xenograft model. The drug administration was done for first 14 days and the tumor growth was monitored until 113 days. The tumor size was measured with a caliper and the tumor volume was calculated based on modified ellipsoidal formula: long axis × short axis^2^ × *π*/6. The mice body weights were measured periodically to assess toxicity. At the end of the experiment, tumors were extracted from mice for wet weight measurement. The tumor tissues were then snap frozen with liquid nitrogen for following western blot analysis.

2.11. Measurement of intracellular thioredoxin activity {#sec2.11}
-------------------------------------------------------

Cells were treated with or without entinostat for 6 h. After washing with PBS, cells were harvested with a cell scraper. The cell suspension was sonicated using a probe sonicator at 50% magnitude for three times on ice. Thioredoxin activity was evaluated from the sonicated cell lysate with a Fluorescent Thioredoxin Activity Assay Kit (Caymen Chemicals, Ann Arbor, MI, USA). The assay was conducted according to the manufacturer\'s instructions.

2.12. Comet assay {#sec2.12}
-----------------

Cellular DNA damage was detected at a single cell level using the comet assay (single cell gel electrophoresis assay[@bib17]. Briefly, cells were treated with drugs for 48 h. Cells were then harvested, suspended in 1% low melting-point agarose gel (Affymetrix, Santa Clara, CA, USA) and spread on a glass slide. The slide was immersed in cell lysis buffer (2.5 mol/L NaCl, 100 mmol/L EDTA and 10 mmol/L Tris base) at 4 °C overnight prior to electrophoresis at 300 mA for 30 min. Propidium iodide (2.5 μg/mL) was added to the slide for DNA staining. The slide was then rinsed with PBS three times to remove residual dye. Single cell comet images were obtained under a Zeiss AxioObserver Z1 fluorescence microscope (Carl Zeiss). Image J software (NIH, Bethesda, MA, USA) was used for quantitative analysis of DNA damage.

2.13. Detection of ROS {#sec2.13}
----------------------

Cellular ROS was detected with CellROX Green cell-permeable fluorescence indicator (Thermo Fisher Scientific). Cells were treated with drugs for indicated time points and CellROX Green solution (2.5 mmol/L) was added to the cells to make the final concentration of the indicator as 5 μmol/L. After incubation for 30 min, cells were rinsed with PBS three times. Cells were filtered through a mesh filter to secure single-cell suspension prior to flow cytometry analysis. Accuri C6 flow cytometry was used for ROS detection and analysis.

2.14. Drug combination analysis {#sec2.14}
-------------------------------

The BRCA1 deficient breast cancer cell lines (HCC1937, SUM-149, and MDA-MB-436) were treated with drug alone or combination of OTX-015 and entinostat at various concentrations for 72 h. The cell growth was measured with Alamarblue and drug effects were input into CompuSyn software (ComboSyn, Paramus, NJ, USA) for drug combination analysis. The software generated combination index (CI) value for each cell line. CI value \< 1 indicates synergistic effect, CI value = 1 indicates additive effect, and CI value \> 1 indicates antagonistic effect.

2.15. Statistical analysis {#sec2.15}
--------------------------

Student\'s *t*-test was used for analyzing statistical difference between two groups. The *P* values less than 0.05 were considered significant. Statistical test for patient\'s survival was conducted with log-rank test. All the statistical evaluation was performed *via* GraphPad Prism 6.0 software.

3. Results {#sec3}
==========

3.1. HDAC inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells {#sec3.1}
-------------------------------------------------------------------------------------

In our previous epigenetics drug library screening, HDAC inhibitors (HDACi) were identified as synthetic lethality hits in BRCA1 deficient breast cancer cells[@bib11]. Here we used two BRCA1 isogenic breast cancer cell pairs, including HCC1937 BRCA1 isogenic (HCC1937-*BRCA1*^+/+^ and HCC1937-*BRCA1*^−/−^) and T47D BRCA1 isogenic (T47D-shCTRL and T47D-sh*BRCA1*) cell lines, to validate the synthetic lethality effects of the HDACi. Three HDACi, including entinostat (class I HDACi), vorinostat (pan-HDACi), and mocetinostat (class I HDACi) showed strong synthetic lethality effects in both colony formation ([Fig. 1](#fig1){ref-type="fig"}A) and cell viability assays ([Fig. 1](#fig1){ref-type="fig"}B--D). Entinostat and mocetinostat are class-I HDACi while vorinostat is a pan-HDACi, suggesting that class I HDACs, in particular HDAC1 and 3, could be targets of the BRCA1 synthetic lethality. Among the three HDACi, entinostat showed the strongest selectivity for BRCA1-deficient breast cancer cells ([Fig. 1](#fig1){ref-type="fig"}B). Hence, we mainly used entinostat for the follow-up studies. Next we analyzed cell cycle and annexin V staining in cells treated with entinostat to assess apoptosis induction. Entinostat treatment significantly increased sub-G1 population in HCC1937-*BRCA1*^−/−^, but not in HCC1937-*BRCA1*^+/+^ cells, indicating a selective induction of apoptosis in BRCA1-deficient cells ([Fig. 1](#fig1){ref-type="fig"}E). Further, annexin V staining cleared showed that entinostat selectively induced apoptosis in HCC1937-*BRCA1*^−/−^ cells ([Fig. 1](#fig1){ref-type="fig"}F). The selective apoptosis induction was further verified with nuclear morphology of the cells treated with entinostat ([Fig. 1](#fig1){ref-type="fig"}G) and Western blots of caspase-3 and PARP-1 cleavage ([Fig. 1](#fig1){ref-type="fig"}H).Figure 1Synthetic lethality between HDAC inhibition and BRCA1 deficiency. (A) The effect of HDAC inhibitors on colony formation of T47D BRCA1 wildtype (shCTRL) and BRCA1 knock-down (sh*BRCA1*) cell lines was tested. Cells were treated with the compounds for 15 days and cell colonies were stained with crystal violet reagent. (B)--(D) The effect of HDAC inhibitors on the cell viability of HCC1937 BRCA1 isogenic cell lines was tested. Cells were treated with the compounds for 3 days and cell viability was determined by alamarblue assay. (E) and (F) Flow cytometry was performed to analyze sub-G1 cell population (E) and annexin V-FITC staining (F) of HCC1937 BRCA1 isogenic cell lines after treated with 5 μmol/L entinostat for 72 h. (G) The effect of HDAC inhibitors on the nuclear morphology of HCC1937 BRCA1 isogenic cell lines was tested. Cells were treated with 5 μmol/L entinostat, vorinostat or mocetinostat for 72 h. Cell nuclei were stained with hoechst33342 reagent and observed under a fluorescent microscope. Scale bar = 100 μm. (H) Western blot analysis for PARP1 and cleaved caspase-3 in HCC1937 BRCA1 isogenic cells treated with 5 μmol/L entinostat for 72 h. Data are mean ± SD, \*\**P* \< 0.01 between two groups.Figure 1

3.2. Class I HDAC inhibition and BRCA1 deficiency is synthetic lethal in breast cancer *in vivo* {#sec3.2}
------------------------------------------------------------------------------------------------

To assess the synthetic lethality effect *in vivo*, we conducted mouse tumor xenograft experiments with HCC1937 and T47D BRCA1 isogenic breast cancer cells. All mice were implanted bilaterally with *BRCA1*^+/+^ and *BRCA1*^−/−^ breast cancer cells and were given entinostat (10 mg/kg) intraperitoneally for 2 weeks. The tumor growth was observed until 39 days for HCC1937 BRCA1-isogenic tumors and 113 days for T47D BRCA1-isogenic tumors since the start of the treatment. Entinostat treatment showed a marginal antitumor activity on HCC1937-*BRCA1*^+/+^ tumor, with the inhibition rate of 43%. Whereas it strongly inhibited the growth of HCC1937-*BRCA1*^−/−^ tumors, with the inhibition rate of 74% ([Fig. 2](#fig2){ref-type="fig"}A and B). The tumor wet weight measurement also showed a selective antitumor effect of entinostat against HCC1937-*BRCA1*^−/−^ tumors ([Fig. 2](#fig2){ref-type="fig"}C). Entinostat at 20 mg/kg showed a similar inhibition profile with 10 mg/kg dosage (data not shown). Similar results were observed in T47D BRCA1-isogenic tumor xenografts. Entinostat treatment almost completely stopped the growth of T47D-sh*BRCA1* tumors (inhibition rate = 84%), while it had marginal antitumor effect on T47D-shCTRL tumors (inhibition rate = 43%) ([Fig. 2](#fig2){ref-type="fig"}D--F). No apparent toxicity was observed under these treatment conditions ([Supporting Information Figs. S1A and B](#appsec1){ref-type="sec"}). These data demonstrated that synthetic lethality between HDAC and BRCA1 occurs *in vivo*.Figure 2*In vivo* synthetic lethality between HDAC inhibition and BRCA1 deficiency. (A)--(C) The effect of entinostat on the tumor growth of HCC1937 BRCA1 isogenic cancer was tested. SCID/NOD mice bearing HCC1937 *BRCA1*^+/+^ (A) or *BRCA1*^−/−^ (B) tumor were given vehicle or entinostat (10 mg/kg) for 14 days and tumor volume was measured until the end of the experiment. Tumor wet weight was measured at the end of the xenograft experiments (C) (*n* = 5). (D)--(F) The effect of entinostat on the tumor growth of HCC1937 BRCA1 isogenic cancer was tested. Nude mice bearing T47D shCTRL (D) or sh*BRCA1* (E) tumor were given vehicle or entinostat (10 mg/kg) for 14 days and tumor volume was measured until the end of the experiment. Tumor wet weight was measured at the end of the xenograft experiments (F) (*n* = 4). (G)--(N) The effect of BRCA1 status and HDAC1/3 expression on breast cancer patient survival was analyzed using the clinical data from the METABRIC. The patients were sub-grouped according to the BRCA1 mutation status and the expression levels of HDAC1 and 3, and the overall survival from each subgroup was analyzed. Data are mean ± SD, \**P* \< 0.05, \*\**P* \< 0.01 between two groups.Figure 2

We further analyzed the potential of the synthetic lethality between BRCA1 and class I HDAC using the clinical data of breast cancer patients. We downloaded 240 breast cancer patients\' data with *BRCA1* mutation and gene expression status of *HDAC1* and *3* from METABRIC project (<http://molonc.bccrc.ca/aparicio-lab/research/metabric/>)[@bib18]. Based on *BRCA1* mutation status (+/+ or −/−) and *HDAC1/3* expression status (high or low), the patients were divided and grouped into 8 subgroups, including 1) *BRCA1*^−/−^, *HDAC1*^*low/high*^, 2) *BRCA1*^−/−^, *HDAC3*^*low/high*^, 3) *BRCA1*^−/−^, *HDAC1*^*low*^, *HDAC3*^*low/high*^, 4) *BRCA1*^−/−^, *HDAC1*^*high*^, *HDAC3*^*low/high*^, 5) *BRCA1*^+/+^, *HDAC1*^*low/high*^, 6) *BRCA1*^+/+^, *HDAC3*^*low/high*^, 7) *BRCA1*^+/+^, *HDAC1*^*low*^, *HDAC3*^*low/high*^, 8) *BRCA1*^*+/+*^, *HDAC1*^*high*^, *HDAC3*^*low/high*^. Either the *HDAC1*^*low/high*^ ([Fig. 2](#fig2){ref-type="fig"}G) or the *HDAC3*^*low/high*^ ([Fig. 2](#fig2){ref-type="fig"}H) did not show significant difference in patient\'s survival in the *BRCA1*^−/−^ patient cohort. Similar results were observed with the *BRCA1*^+/+^ patient cohort ([Fig. 2](#fig2){ref-type="fig"}K,L). Interestingly, the *BRCA1*^−/−^ patient cohort with the *HDAC1*^*low*^, *HDAC3*^*low*^ showed significant longer overall survival compared to those with the *HDAC1*^*low*^, *HDAC3*^*high*^ ([Fig. 2](#fig2){ref-type="fig"}I) or the *HDAC1*^*high*^, *HDAC3*^*low/high*^ ([Fig. 2](#fig2){ref-type="fig"}J). There was no significant difference in overall survival between the *HDAC1/3* expression status in the *BRCA1*^+/+^ patient cohorts ([Fig. 2](#fig2){ref-type="fig"}M,N). These data suggested that down-regulation of both HDAC1 and 3 might provide survival benefit to patients with BRCA1 deficient breast cancer. Our results also suggested that entinostat as a broad inhibitor of class I HDACs, may serve as a possible synthetic lethality drug for patients with BRCA1 deficient breast cancer.

3.3. Inhibition of class I HDAC provokes cellular oxidative stress and DNA damage responses {#sec3.3}
-------------------------------------------------------------------------------------------

To investigate the mechanism underlying the synthetic lethality, we performed transcriptome profiling of HCC1937 BRCA1 isogenic cells treated with control and entinostat. The differentially expressed genes were obtained and subjected to the Reactome signal pathway analysis[@bib19]. A number of genes involved in apoptosis induction and extracellular matrix organization were up-regulated by entinostat treatment ([Fig. 3](#fig3){ref-type="fig"}A). Interestingly, genes involved in formation of the cornified envelope, keratinization and DNA damage stress pathways were also significantly upregulated. Whereas, a large part of down-regulated genes were cell cycle and mitosis related genes ([Fig. 3](#fig3){ref-type="fig"}B). HDACs, particularly class I HDACs, are highly linked to cell cycle regulation since they form a multimeric corepressor complex with E2F/RB1/RBP1/Sin3 to regulate cell cycle progression[@bib20], [@bib21]. The class I HDACs also regulate p21CIP1/WAF1 expression to regulate G1 cell cycle transition[@bib22]. Furthermore, it is also well known that class I HDACs directly regulate P53 stability and transcriptional activity by regulating P53 acetylation[@bib23], which is critical for apoptosis induction[@bib24], [@bib25]. On the other hand, the two signal pathways that were up-regulated: formation of the cornified envelope and keratinization, are highly related to cellular oxidative stress[@bib26], [@bib27]. In addition, DNA damage stress genes that were up-regulated also related phenotype to cellular oxidative stress. The relationship between HDAC and cellular oxidative stress has been previously reported[@bib28], [@bib29]. The study conducted by Feingold et al.[@bib28] and Petruccelli et al.[@bib29] demonstrated that HDAC inhibition induces cellular pro-oxidant protein, TXNIP and heavily increases ROS and DNA damage. We thus hypothesized that class I HDAC inhibition could induce cellular oxidative stress, resulting in heavy DNA damages that are detrimental to BRCA1 deficient breast cancer cells. We then analyzed the protein levels that are involved in cellular oxidative response and DNA damage, such as TXNIP, HO-1 and *γ*-H2AX, in cells treated with entinostat. Histone acetylation status was analyzed in parallel as a positive control. Entinostat treatment significantly increased TXNIP level in a biphasic manner: increased in earlier time points (peak at 8 h) and returned to background level at 24 h, in HCC1937-*BRCA1*^−/−^ cells ([Fig. 3](#fig3){ref-type="fig"}C). Oxidative stress marker HO-1 and DNA damage marker *γ*-H2AX levels were also significantly increased by the entinostat treatment ([Fig. 3](#fig3){ref-type="fig"}C and [Fig. S1C](#appsec1){ref-type="sec"}). Similar biphasic induction of TXNIP and significant increase in HO-1 and *γ*-H2AX were observed in T47D-sh*BRCA1* cells treated with entinostat ([Fig. 3](#fig3){ref-type="fig"}D and [Fig. S1D](#appsec1){ref-type="sec"}). These data suggested that entinostat indeed increased the pro-oxidant protein TXNIP and provoked cellular oxidative stress and DNA damage responses in BRCA1 deficient breast cancer cells. The RT-qPCR analysis of *TXNIP* mRNA level also showed a biphasic increase in *TXNIP* expression by entinostat ([Fig. 3](#fig3){ref-type="fig"}E). We next performed ChIP experiments to test whether the increase in *TXNIP* mRNA by entinostat was due to the de-repression of its transcription resulting from the inhibition of HDAC activity on the promoter of *TXNIP*. Treatment of the HCC1937 BRCA1^−/−^ cells with entinostat for 6 h significantly increased the histone H4 acetylation on the *TXNIP* promoter ([Fig. 3](#fig3){ref-type="fig"}F). This result suggested that the increase in *TXNIP* expression by entinostat was from the direct inhibitory effect on HDAC activity on its promoter. We next examined whether the entinostat effect on cellular oxidative stress and DNA damage response was selective to BRCA1 deficient cells. Basal levels of TXNIP and HO-1 were higher in HCC1937-*BRCA1*^−/−^ than in HCC1937-*BRCA1*^+/+^ cells ([Fig. 3](#fig3){ref-type="fig"}G), which was in agreement with previous reports that BRCA1 plays a role in antioxidant signaling. Upon entinostat treatment, HO-1 level was significantly increased in HCC1937-*BRCA1*^−/−^, but not in HCC1937-*BRCA1*^+/+^ cells. Likewise, entinostat-induced *γ*-H2AX was significantly higher in HCC1937-*BRCA1*^−/−^ than in HCC1937-*BRCA1*^+/+^ cells. Whereas the acetylation of histones was similarly increased in both cell types by entinostat, demonstrating that entinostat-induced oxidative stress and DNA damage response was much stronger in BRCA1-deficient breast cancer cells ([Fig. 3](#fig3){ref-type="fig"}G). Similar results were observed in vorinostat ([Fig. 3](#fig3){ref-type="fig"}H) and mocetinostat treatment ([Fig. 3](#fig3){ref-type="fig"}I), suggesting that class I HDAC inhibition provoked cellular oxidative stress and DNA damage responses more selectively in BRCA1 deficient cells.Figure 3Transcriptome profiling to explore the mechanism of the synthetic lethality. (A) and (B) REACTOME signal pathway analysis for the RNA sequencing results is shown. HCC1937 BRCA1 isogenic cells were treated with 5 μmol/L entinostat for 24 h and total RNA was extracted for RNA sequencing. The gene expression profiles were analyzed with REACTOME signal pathway database. The pathway genes that were significantly up- (A) and down-regulated (B) by entinostat are shown. (C) and (D) The effect of entinostat on cellular oxidative stress and DNA damage was examined. HCC1937 *BRCA1*^−/−^ (C) or T47D sh*BRCA1* (D) cells were treated with 5 μmol/L entinostat for indicated time points and Western blots for proteins involved in oxidative stress and DNA damage responses were analyzed. GAPDH was used as an internal control. (E) RT-qPCR analysis for the *TXNIP* mRNA level was examined in HCC1937 BRCA1 isogenic cells treated with entinostat. (F) Chromatin immunoprecipitation (ChIP) of *TXNIP* promoter using anti-acetyl histone H4 antibody is shown. HCC1937 *BRCA1*^−/−^ cells were treated with 5 μmol/L entinostat for 6 h and processed for ChIP using a rabbit IgG (control) or anti-acetyl histone H4 antibody. The ChIP DNA was subjected to PCR amplification with a primer pair specific for *TXNIP* promoter. (G) and (I) The effect of HDAC inhibitors, entinostat (class I-HDACi, G), vorinostat (pan-HDACi, H), and mocetinostat (class I-HDACi, I) on histone acetylation, cellular oxidative stress and DNA damage responses was examined in HCC1937 BRCA1 isogenic cell lines. Data are mean ± SD, \**P* \< 0.05, \*\**P* \< 0.01 between two groups.Figure 3

3.4. Entinostat induces ROS and DNA damage, which is the major cause for synthetic lethality between HDAC inhibition and BRCA1 deficiency {#sec3.4}
-----------------------------------------------------------------------------------------------------------------------------------------

Our expression profile showed that entinostat treated breast cancer cells provoked strong oxidative stress and DNA damage responses. We then analyzed cellular ROS and DNA damages in cell treated with entinostat. Entinostat increased cellular ROS level in both HCC1937-*BRCA1*^+/+^ and HCC1937-*BRCA1*^−/−^ cells ([Fig. 4](#fig4){ref-type="fig"}A). The level of ROS induction was much higher in HCC1937-*BRCA1*^−/−^ cells, which is consistent with the TXNIP and HO-1 levels in these cells ([Fig. 3](#fig3){ref-type="fig"}E). In comet assay, entinostat showed a marginal effect in DNA damage in HCC1937-*BRCA1*^+/+^, while it induced severe DNA damages in HCC1937-*BRCA1*^−/−^ cells ([Fig. 4](#fig4){ref-type="fig"}B and C). Co-treatment with an antioxidant *N*-acetylcysteine (NAC) significantly reversed the entinostat-induced DNA damage in HCC1937-*BRCA1*^−/−^ cells ([Fig. 4](#fig4){ref-type="fig"}B and C), suggesting that DNA damages induced by entinostat was largely due to the ROS. The NAC rescue effect was also observed in the synthetic lethality where entinostat inhibition on HCC1937-*BRCA1*^−/−^ cell viability was significantly reversed by NAC co-treatment ([Fig. 4](#fig4){ref-type="fig"}D and E). These results suggested that entinostat induced cellular ROS and this effect facilitated DNA damages in HCC1937-*BRCA1*^−/−^ cells where DNA double-strand break repair function is impaired.Figure 4Induction of reactive oxygen species (ROS) and DNA damage in *BRCA1*^−/−^ cells by entinostat. (A) The effect of entinostat on cellular ROS in HCC1937 BRCA1 isogenic cells was tested. HCC1937 BRCA1 isogenic cells were treated with 5 μmol/L entinostat for 6 h and intracellular ROS was detected under a flow cytometry with CellROX green fluorescence dye. (B) The effect of entinostat on DNA damage in HCC1937 BRCA1 isogenic cells was tested with the comet assay. HCC1937 BRCA1 isogenic cells were treated with entinostat alone (5 μmol/L) or in combination with *N*-acetylcysteine (NAC, 5 mmol/L) for 24 h and the DNA damage levels were assessed by comet assay. Scale bar = 100 μm. (C) The DNA tails (50 tails/group) were measured by Image J software and the data were plotted with Graphpad prism 6.0. (D) and (E) The effect of entinostat on cell viability in HCC1937 BRCA1 isogenic cells and its reversal by NAC was tested. Representative cell images (D) and alamarblue data (E) are shown. Scale bar = 400 μm. (F) The effect of entinostat on thioredoxin (TXN) activity was examined. HCC1937 BRCA1 isogenic cells were treated with 5 μmol/L entinostat for 6 h and intracellular TXN activity was measured with a Fluorescent Thioredoxin Activity Assay Kit. (G) The effect of TXNIP silencing on entinostat-induced ROS in HCC1937 *BRCA1*^−/−^ cells was tested. HCC1937 *BRCA1*^−/−^ cells were transfected with 2 nmol/L TXNIP siRNA for 24 h prior to dosing with 5 μmol/L entinostat. After 6 h incubation, intracellular ROS was measured with CellROX green kit. (H) The effect of TXNIP silencing on entinostat-induced synthetic lethality in HCC1937 *BRCA1*^−/−^ cells was tested. HCC1937 *BRCA1*^−/−^ cells were transfected with 2 nmol/L TXNIP siRNA for 24 h prior to dosing with 5 μmol/L entinostat. After additional 72 h incubation, the cell viability was assessed with the alamarblue assay. \**P* \< 0.05; \*\**P* \< 0.01 between two indicated groups. (I) The reversal effect of TXNIP silencing on entinostat-induced oxidative stress and DNA damage responses was examined in HCC1937 *BRCA1*^−/−^ cells. Data are mean ± SD, \**P* \< 0.05, \*\**P* \< 0.01 between two groups.Figure 4

Since we observed that a pro-oxidant TXNIP was significantly increased in HCC1937-*BRCA1*^−/−^ cells upon treatment with entinostat, we next examined the role of TXNIP in the synthetic lethality effect. TXNIP works by inhibiting an antioxidant protein thioredoxin through disulfide exchange[@bib30]. We first measured cellular thioredoxin activity after treated with entinostat. Entinostat marginally, but significantly inhibited thioredoxin activity in cells with stronger effect in HCC1937-*BRCA1*^−/−^ cells ([Fig. 4](#fig4){ref-type="fig"}F). Next, we silenced TXNIP in cells treated with or without entinostat and measured intracellular ROS level. Entinostat significantly increased ROS in HCC1937-*BRCA1*^−/−^ cells but this effect was partially reversed by TXNIP siRNA ([Fig. 4](#fig4){ref-type="fig"}G, upper panel). The reversal effect was well correlated with TXNIP protein level ([Fig. 4](#fig4){ref-type="fig"}G, lower panel). We further observed that entinostat-induced inhibition of HCC1937-*BRCA1*^--/--^cell viability was significantly reversed by the silencing of TXNIP ([Fig. 4](#fig4){ref-type="fig"}H). As evidenced by Western blots, treatment with TXNIP siRNA strongly reversed entinostat-induced TXNIP and the expression of HO-1 and *γ*-H2AX in HCC1937-*BRCA1*^−/−^ cells ([Fig. 4](#fig4){ref-type="fig"}I). However, TXNIP siRNA did not affect histone acetylation by entinostat. These data strongly suggested that entinostat-induced increase in TXNIP level played a key role in the synthetic lethality.

3.5. The combined inhibition of class I HDAC and BET enhanced the synthetic lethality effect in BRCA1 deficient breast cancer cells {#sec3.5}
-----------------------------------------------------------------------------------------------------------------------------------

We previously reported that BET inhibition reduced TXNIP level by inhibiting MYC and activating MondoA:MLX transcription factor[@bib11]. This led to an increase in intracellular ROS and heavy DNA double strand breaks in BRCA1 deficient breast cancer cells. Our present study revealed that class I HDAC inhibition de-repressed *TXNIP* transcription, thereby increasing ROS. Therefore, we hypothesized that the combination of HDAC inhibitor and BET inhibitor could lead greater oxidative stress and DNA damage in BRCA1 deficient breast cancer cells compared to the single agent treatment. Indeed, co-treatment of cells with entinostat and a BET inhibitor OTX-015 significantly enhanced cellular ROS level in HCC1937-*BRCA1*^−/−^ cells compared to a single agent treatment ([Fig. 5](#fig5){ref-type="fig"}A). Consistently, same result was observed in comet assay where co-treatment with HDAC and BET inhibitors greatly increased cellular DNA damage in HCC1937-*BRCA1*^−/−^ cells ([Fig. 5](#fig5){ref-type="fig"}B and C). As a result, the two drug combination strongly induced synthetic lethality in HCC1937-*BRCA1*^−/−^ cells by inducing apoptosis ([Fig. 5](#fig5){ref-type="fig"}D and E). Lastly, we examined the effect of the two drug combination in a panel of breast cancer cell lines with different BRCA1 status. Either single agents or combination of the two drugs showed selective inhibition on BRCA1 deficient breast cancer cells with the drug combination having stronger effect ([Fig. 5](#fig5){ref-type="fig"}F and [Support Information Fig. S2](#appsec1){ref-type="sec"}). To determine whether the combination effect of HDAC and BET inhibitors is synergistic or not, we analyzed drug CI of entinostat and OTX-015 in three BRCA1 deficient breast cancer cell lines (HCC1937, SUM-149 and MDA-MB-436). The calculated CI values indicated that the combination of entinostat and OTX-015 had synergetic anti-cancer effect on the three BRCA1 deficient breast cancer cell lines ([Fig. 5](#fig5){ref-type="fig"}G--I). Altogether, our results suggested that combined inhibition of class I-HDAC and BET boosted up cellular oxidative stress and resulting DNA double-strand breaks and exerted strong synthetic lethality in BRCA1 deficient breast cancer cells.Figure 5Enhanced synthetic lethality effect by the combination of bromodomain and extraterminal motif (BET) and HDAC inhibition in BRCA1 deficient breast cancer cells. (A)--(D) The effect of single or combination of the inhibitors of BET (OTX-015) and HDAC (entinostat) on ROS induction (A), DNA damage (B (Scale bar = 100 μm) and C), and cell viability (D) (Scale bar = 400 μm) in HCC1937 BRCA1 isogenic cells is shown. (E) Enhanced apoptosis induction in HCC1937 *BRCA1*^−/−^ cells by the combination of BET and HDAC inhibitors is shown. Western blots of cleaved caspase-3 and PARP1 were used as apoptosis indicators. (F) The synthetic lethality effect of the combination of BET and HDAC inhibitors in a panel of breast cancer cells with different BRCA1 status was tested. The cells were treated with single or combination of 0.25 × concentration of IC~50~ of OTX-015 and entinostat for 72 h and alamarblue assay was performed to assess cell viability. The combination of other concentrations (4×, 2×, 1×, 0.5× IC~50~) is presented in [Supporting Information Fig. S2](#appsec1){ref-type="sec"}. (G)--(I) BRCA1 deficient breast cancer cells, including HCC1937 (G), SUM-149 (H) and MDA-MB-436 (I) were treated with the drug alone or combination of entinostat and OTX-015 at various concentrations for 72 h and the combination indices (CI) were determined with CompuSyn software. Data are mean ± SD, \*\**P* \< 0.01 between two groups.Figure 5

4. Discussion {#sec4}
=============

In the present study, we identified that HDAC inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells. The synthetic lethality effect has been thoroughly validated in two different BRCA1 isogenic breast cancer pairs *in vitro* and *in vivo* mouse models. Although we failed to define precise isoform(s) of HDAC that mediated the synthetic lethality, testing with the 3 class-specific HDAC inhibitors and clinical data analyses of breast cancer patients suggested that class I HDACs, in particular HDAC1 and 3, are together involved in the synthetic lethality with BRCA1. HDACs are a family of deacetylase enzymes that remove acetyl groups from an *N*-acetyl lysine amino acid on a histone or other non-histone protein substrates. Class I HDACs, such as HDAC1, 2, and 3 are found primarily in the nucleus, suggesting their primary role in gene transcription regulation[@bib31]. Class I HDACs are known to repress the transcription and the function of a number of tumor suppressors, including P21^CIP1/WAF1^[@bib32], E-cadherin[@bib33], P53[@bib34], BRCA1[@bib35] and retinoic acid receptor-beta (RAR*β*2)[@bib36]. Overexpression of HDACs and aberrant recruitment of HDACs to the promoter of the tumor suppressors have been observed in a variety of tumors, making it a promising drug target for cancer treatment.

A number of recent studies commonly addressed that HDAC inhibition elevated cellular ROS[@bib37], [@bib38], [@bib39], [@bib40], which is likely to be one of primary mechanisms of cancer cell death. Pre-exposure of cancer cells to antioxidants was able to protect the cells from HDACi-mediated cell death[@bib41]. However, the mechanism of such oxidative stress induction by HDAC inhibition remains to be fully elucidated. Accumulating evidence has suggested that HDAC directly represses cellular pro-oxidant proteins, such as TXNIP and NADPH oxidases[@bib13], [@bib42]. TXNIP has been identified from yeast-two-hybrid screen as a thioredoxin-interacting protein[@bib43]. Thioredoxin is a multifunctional antioxidant protein involved in reduction of other protein disulfide[@bib44] and H~2~O~2~[@bib45], [@bib46], in DNA synthesis as a hydrogen donor[@bib47] and in redox regulation of transcription factors[@bib48], which plays an important role in cellular redox regulation. TXNIP binds to thioredoxin and inhibits its disulfide reductase activity[@bib49], thus promoting cellular oxidative stress and apoptosis. TXNIP expression is negatively correlated with tumor progression and its high expression is significantly associated with better treatment outcomes, hence being considered as a tumor suppressor[@bib50], [@bib51]. In our study, we observed that TXNIP expression was sharply increased in breast cancer cells treated with HDACi. At later time points, however TXNIP level went down to a basal level. The early increase of the TXNIP level was likely due to the HDAC inhibition-induced de-repression of *TXNIP* transcription as local histones around the *TXNIP* promoter were highly acetylated upon entinostat treatment. The level of the transcription factor MLXIP (MondoA) remained unchanged at early treatment period, while it was reduced at later treatment period, suggesting that the reduced TXNIP level at later time point was likely due to the reduction of its transcription activator level. The transient increase of TXNIP was sufficient to induce cellular oxidative stress and DNA damage responses as evidenced by prolonged expression of HO-1 and *γ*-H2AX under entinostat treatment. Silencing of TXNIP markedly reversed the expression of HO-1 and *γ*-H2AX, as well as the entinostat-induced ROS generation, DNA damage and apoptosis induction in BRCA1 deficient breast cancer cells. These data demonstrate that TXNIP is a key factor mediating the entinostat-induced synthetic lethality.

BRCA1-deficient cells are highly sensitive to DNA damaging agents. With its major role in homology-directed repair, cells with BRCA1 mutations are unable to properly repair DNA double-strand breaks, leading to increase in sensitivity to DNA damaging agents[@bib52]. With this in mind, we combined an HDACi with a BETi that we previously identified as a synthetic lethality drug for BRCA1 deficient breast cancer cells. The combination of the two ROS-inducing agents significantly promoted cellular oxidative stress and DNA damages, and thereby induced apoptosis and synergetic anticancer effect in BRCA1 deficient breast cancer cells, while it showed negligible effect in BRCA1 wildtype cells. These data suggest that the combination of HDACi and BETi could provide stronger synthetic lethality effect in BRCA1 deficient breast cancer and serve as a treatment option to avoid drug resistance associated with HDACi or BETi monotherapy.

HDAC inhibition can exert pleiotropic effect in several biological pathways as HDAC is involved in general epigenetic gene expression regulation. Hence, it cannot be ruled out that mechanisms other than TXNIP-ROS pathway may be also involved in the HDAC inhibition-induced synthetic lethality in BRCA1 deficient breast cancer cells. For example, HDAC inhibition indirectly down-regulates the expression of proteins involved in DNA damage repair, such as ATM[@bib53] and RAD52[@bib54], whose loss of expression was reported to sensitize BRCA1 deficient cancer cells[@bib55], [@bib56]. Further study is necessary to elucidate the involvement of these DNA damage repair pathways in the synthetic lethality between HDAC and BRCA1.

In summary, we show that HDAC inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells *via* elevating oxidative stress and DNA damage-induced apoptosis. Clinical investigation of HDACi alone or in combination with BETi is warranted for patients with BRCA1 deficient breast cancer.
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